Nektar Therapeutics (FRA:ITH0) Momentum Rank: 8 (As of Sep. 21, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ITH0 Nektar Therapeutics FRA:ITH0
51 GF Score
Price €60.14
GF Value €4.61
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Momentum Rank?

Nektar Therapeutics FRA:ITH0 +0.03% 51 Momentum Rank is 8 as of Sep. 21, 2026, which is 100% above its 10-year median of 4.00. GuruFocus rates FRA:ITH0 with a GF Score™ of 51/100 and a GF Value™ of €4.61 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Nektar Therapeutics has the Momentum Rank of 8.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Nektar Therapeutics Momentum Rank Related Terms

FRA:ITH0 vs PHVS, PGEN, VERA: Momentum Rank Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Momentum Rank falls into.


FRA:ITH0
51GF Score
Nektar Therapeutics FRA:ITH0
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 8 mean?
Nektar Therapeutics (FRA:ITH0) has a Momentum Rank of 8 as of Sep. 21, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Nektar Therapeutics and its competitors. This is 100% above median its historical median of 4.00. Over the past decade, Nektar Therapeutics' Momentum Rank has ranged from 1.00 to 10.00.
Is Nektar Therapeutics' Momentum Rank too high?
Nektar Therapeutics' current Momentum Rank of 8 is 100% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Nektar Therapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Momentum Rank compare to PHVS and PGEN?
Nektar Therapeutics' Momentum Rank of 8 can be compared against companies in the Biotechnology industry. Historically, Nektar Therapeutics' own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Momentum Rank is 8, which is 100% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (FRA:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.61, compared to a current price of €60.14 — trading 1204.6% above its estimated fair value. The current Momentum Rank is 8, which is 100% above median its 10-year median of 4.00. Nektar Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Nektar Therapeutics (FRA:ITH0), the current Momentum Rank is 8 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €60.14 is trading 1204.6% above its estimated GF Value™ of €4.61. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:ITH0:

  • Momentum Rank: 8 (100% above median its 10-year median of 4.00)
  • GF Value™: €4.61 vs. price of €60.14 (1204.6% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
51GF Score

Get the complete analysis for FRA:ITH0

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.14
Price
€4.61
GF Value